公开(公告)号：US20240309394A1

公开(公告)日：2024-09-19

申请号：US18270366

申请日：2021-12-26

Applicant: BETTERSEEDS LTD

Inventor： Tal SHERMAN ,  Ido MARGALIT ,  Shira COREM

IPC: C12N15/82 ,  C12N9/10 ,  C12N9/22 ,  C12N9/78 ,  C12N15/11 ,  C12Q1/6895

CPC classification number: C12N15/8274 ,  C12N9/1022 ,  C12N9/1059 ,  C12N9/1092 ,  C12N9/22 ,  C12N9/78 ,  C12N15/111 ,  C12N15/8213 ,  C12Q1/6895 ,  C12Y202/01006 ,  C12Y204/01012 ,  C12Y205/01019 ,  C07K2319/00 ,  C12N2310/20 ,  C12N2800/80 ,  C12Q2600/13 ,  C12Q2600/156

Abstract: The present invention discloses a modified Cannabis plant exhibiting herbicide resistance (HR) as compared to a Cannabis plant absent of such modification. The modified plant comprises at least one genetically modified HR-related gene comprising at least one mutation conferring herbicide resistance to the plant. The present invention further discloses methods for producing the same.

公开(公告)号：US12084691B2

公开(公告)日：2024-09-10

申请号：US17546810

申请日：2021-12-09

Applicant: Arizona Board of Regents on behalf of Arizona State University

Inventor： Radwa Ewaisha ,  Samira Kiani ,  Shayesteh Roshdi Ferdosi ,  Karen Anderson ,  Farzaneh Moghadam ,  Sri Krishna ,  Mo Reza Ebrahimkhani

IPC: C12N9/22 ,  A61K48/00 ,  G01N33/573

CPC classification number: C12N9/22 ,  G01N33/573 ,  A61K48/00 ,  C12N2310/20 ,  C12N2800/80 ,  G01N2333/922

Abstract: Provided herein are methods and compositions for reducing an undesirable T cell immune response in human patients prior to and/or during gene therapy using CRISPR/Cas9-based genetic modulation.

公开(公告)号：US12077771B2

公开(公告)日：2024-09-03

申请号：US18327373

申请日：2023-06-01

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY

Inventor： Samira Kiani ,  Mo Reza Ebrahimkhani ,  Jennifer Chapman

IPC: C12N15/85 ,  C12N9/22 ,  C12N15/11 ,  C12N15/115 ,  C12N15/62 ,  C12N15/90

CPC classification number: C12N15/85 ,  C12N9/22 ,  C12N15/11 ,  C12N15/115 ,  C12N15/62 ,  C12N15/907 ,  C12N2310/128 ,  C12N2310/16 ,  C12N2310/20 ,  C12N2501/12 ,  C12N2501/405 ,  C12N2800/80

Abstract: Aspects of the disclosure relate to methods and synthetic regulatory systems for more efficient nuclease-mediated homology-directed repair (HDR). In particular, provided herein are methods for more efficient in vivo and in vitro HDR-based gene editing where the methods comprise introducing into a cell a synthetic regulatory system comprising Cas nuclease, guide RNAs (gRNAs) having various lengths and configured to target distinct nucleotide sequences for simultaneous transcriptional repression (or activation) and genome editing via double stranded break and use of a donor nucleic acid molecule as a template for repair.

公开(公告)号：US20240290421A1

公开(公告)日：2024-08-29

申请号：US18206981

申请日：2023-06-07

Applicant: Algen Biotechnologies, Inc.

Inventor： Spencer Charles Knight ,  Chun-Hao Huang

IPC: G16B20/00 ,  C12N5/09 ,  C12N9/22 ,  C12N15/10 ,  C12N15/11 ,  C12N15/86 ,  G06N20/00 ,  G16B40/20

CPC classification number: G16B20/00 ,  C12N5/0693 ,  C12N5/0694 ,  C12N9/22 ,  C12N15/1058 ,  C12N15/1089 ,  C12N15/1096 ,  C12N15/11 ,  C12N15/86 ,  G06N20/00 ,  G16B40/20 ,  C12N2310/20 ,  C12N2740/15043 ,  C12N2800/80

Abstract: The present disclosure provides methods and systems for identification of genomic regions for therapeutic targeting. A method for identifying one or more genomic regions for therapeutic targeting, which may facilitate re-programming of a cell from one phenotypic state to another, may comprise: providing single-cell RNA-seq data for a plurality of diseased cells and a plurality of normal cells of a cell type; mapping the single-cell RNA-seq data for the plurality of diseased cells and the plurality of normal cells into a latent space corresponding to a plurality of phenotypic states of the cell type; identifying, based at least in part on a topology of the latent space, the one or more genomic regions for therapeutic targeting; and electronically outputting the one or more genomic regions for therapeutic targeting.

公开(公告)号：US20240287452A1

公开(公告)日：2024-08-29

申请号：US18441393

申请日：2024-02-14

Applicant: Seattle Children's Hospital (dba Seattle Children's Research Institute)

Inventor： David J. Rawlings ,  Richard James ,  Shaun W. Jackson ,  Iram Khan ,  King Hung ,  Andrew M. Scharenberg

IPC: C12N5/078 ,  A61K35/17 ,  A61K48/00 ,  C07K14/00 ,  C07K16/00 ,  C12N5/0781 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  C12N15/90

CPC classification number: C12N5/0634 ,  A61K48/0058 ,  C07K14/00 ,  C07K16/00 ,  C12N5/0635 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  A61K35/17 ,  C07K2317/14 ,  C07K2317/21 ,  C12N15/113 ,  C12N2310/20 ,  C12N2501/056 ,  C12N2501/2302 ,  C12N2501/2306 ,  C12N2501/231 ,  C12N2501/2315 ,  C12N2501/24 ,  C12N2501/52 ,  C12N2506/11 ,  C12N2510/00 ,  C12N2510/02 ,  C12N2750/14143 ,  C12N2800/80

Abstract: The present application relates to plasma cells and plasma cell precursors that express a macromolecule, such as a protein, protein mimetic or a peptide and compositions comprising these plasma cells or plasma cell precursors. The application further relates to methods of using and making the plasma cells and plasma cell precursors that express the macromolecule. Methods of treatment comprising administering the plasma cells or plasma cell precursors are also contemplated.

公开(公告)号：US12060586B2

公开(公告)日：2024-08-13

申请号：US16970115

申请日：2019-02-15

Applicant: The Broad Institute, Inc.

Inventor： David R. Liu ,  Weixin Tang

IPC: C12N9/22 ,  C12N15/11 ,  C12Q1/02

CPC classification number: C12N9/22 ,  C12N15/11 ,  C12Q1/02 ,  C12N2310/20 ,  C12N2800/101 ,  C12N2800/107 ,  C12N2800/80

Abstract: Described herein are compositions, vectors, cells, methods, and kits that provide cell data recorder systems for recording cell states. The cell data recorder systems allow for the recording of both the presence and duration of one or more stimuli in a programmable, reproducible, and multiplexable manner. These cell data recorder systems employ a nucleic acid programmable DNA binding protein, such as a Cas9 nuclease, or a fusion protein comprising a nucleic acid programmable DNA binding domain and a nucleic acid editing domain to introduce recordable changes in the genome of a cell or in a plasmid within the cell.

公开(公告)号：US20240261440A1

公开(公告)日：2024-08-08

申请号：US18419370

申请日：2024-01-22

Applicant: The Board of Regents of The University of Texas System

Inventor： Tuo WEI ,  Yehui SUN ,  Qiang CHENG ,  Daniel SIEGWART

IPC: A61K48/00 ,  A61K31/7088 ,  A61K38/46 ,  A61K47/24 ,  A61K47/54 ,  C07K14/705 ,  C12N9/22 ,  C12N15/11 ,  C12N15/88 ,  C12N15/90

CPC classification number: A61K48/0066 ,  A61K31/7088 ,  A61K38/465 ,  A61K47/24 ,  A61K47/543 ,  C07K14/705 ,  C12N9/22 ,  C12N15/11 ,  C12N15/88 ,  C12N15/907 ,  C12N2310/20 ,  C12N2800/80

Abstract: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

公开(公告)号：US12054706B2

公开(公告)日：2024-08-06

申请号：US17830011

申请日：2022-06-01

Applicant: BLUEALLELE CORPORATION

Inventor： Nicholas J. Baltes

IPC: C12N15/10 ,  C12N15/86 ,  C12N15/90

CPC classification number: C12N15/102 ,  C12N15/86 ,  C12N15/907 ,  C12N2310/20 ,  C12N2800/80

Abstract: Methods and compositions for modifying the coding sequence of endogenous genes using rare-cutting endonucleases and transposases. The methods and compositions described herein can be used to modify the coding sequence of endogenous genes.

公开(公告)号：US20240254516A1

公开(公告)日：2024-08-01

申请号：US18634640

申请日：2024-04-12

Applicant: National University Corporation Kobe University

Inventor： Keiji NISHIDA

IPC: C12N15/90 ,  C12N9/22 ,  C12N9/78 ,  C12N15/11

CPC classification number: C12N15/907 ,  C12N9/22 ,  C12N9/78 ,  C12N15/11 ,  C12N15/90 ,  C12Y305/04 ,  C12N2310/20 ,  C12N2800/80

Abstract: The present invention provides a complex containing a nucleic acid sequence-recognizing module and a proteolysis tag, wherein the module is linked to the proteolysis tag, the module specifically binds to a target nucleotide sequence in a double stranded DNA, and the tag consists of (i) a peptide containing 3 hydrophobic amino acid residues at the C-terminal, or (ii) a peptide containing 3 amino acid residues at the C-terminal wherein at least a part of the amino acid residues is substituted by serine

公开(公告)号：US20240254467A1

公开(公告)日：2024-08-01

申请号：US18623704

申请日：2024-04-01

Applicant: LifeEDIT Therapeutics, Inc.

Inventor： Tyson D. Bowen ,  Alexandra Briner Crawley ,  Tedd D. Elich

IPC: C12N9/22 ,  C12N15/63

CPC classification number: C12N9/22 ,  C12N15/63 ,  C12N2310/20 ,  C12N2800/80

Abstract: Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.